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The use of MSCs as a therapeutic agent is proven to be highly successful in many cases. 
However, the effects obtained are often temporary, and not leading to complete recovery. The 
reasons of such phenomenon are discussed in the article and the concept of “triggering effects” 
of MSCs is substantiated. The effect consists of the fact, that signal molecules, secreted by 
MSCs after administration, on one hand reduce the cell damage severity, supports and heals 
the cells. And on the other hand, MSCs induce mobilization and activation of the own (resident) 
stem cells, which replace the damaged cells.  The realization of the therapeutic effect depends 
on the presence or absence of genetically determined disorders. 
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The last fifteen years have witnessed the in­
tense study of mesenchymal stem cells (MSC) 
as a promising remedy of treating a wide range 
of human diseases. This trend is based on the 
extensive fundamental research and techno­
logical elaborations [1], evolving into the in­
creasing number of clinical trials [2–4]. It takes 
a therapeutic preparation a long time to enter 
the market. However, the first samples of MSC 
have already become commercial products, 
although this evident success is accompanied 
with rather numerous reports about low effi­
ciency of MSC, short duration or absence of 
the therapeutic effect [5]. The interpretation of 
even the most successful clinical results of 
MSC application is complicated due to sig­
nificant changes in the original ideas about 
MSC nature [6–8] and the mechanisms of their 
action [9]. Modern views do not deny the ca­
pability of MSC to get differentiated into var­
ious specialized cells, but relate their signifi­
cance in the organism mainly to such signa­
ling­trophic functions as the induction of re­
programming both immune system cells and 
tissue cells in the damaged zone via signaling 
molecules released by MSC [7, 10–13]. When 
the organism is damaged, MSC rebuild their 
metabolism on their own [14].
Different protocols of applying MSC are 
reported in the scientific literature [15; 16]. 
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There are differences in doses, terms, fre­
quency, sources, conditions of obtaining, pa­
thologies, recipients, efficiency of obtained 
results, etc. [8]. Currently the available works 
do not provide specific unambiguous conclu­
sions. Regardless of numerous detailed studies 
on the mechanisms of MSC action [17], it is 
yet to be defined why “therapeutic MSC”, 
introduced from outside, have medicinal effect, 
whereas the inner ones do not. Moreover, 
many cases prove the efficiency of the inner 
MSC after they have been extracted and then 
introduced back.
To find out possible reasons of this phenom­
enon, we have conducted several series of 
experiments with laboratory animals. The task 
was to check our hypothesis that the single­
step introduction of a large amount of MSC 
from outside (regardless of their nature) leads 
to changing metabolism of the whole organism 
towards activation, re­programming and mo­
bilization of its own systems of damage resto­
ration, which have been inactive or blocked in 
a chronically sick organism. These mobilized 
and re­programmed cells of the mentioned sick 
organism start restoring it on their own.
The series of experiments on laboratory 
models of chronic pathologies were conducted 
to analyze the MSC action. One model simu­
lated well-known in scientific literature liver 
damage, cirrhosis, in rats caused by carbon 
tetrachloride. According to histological analy­
ses, these injections during one month resulted 
in the development of fibrosis, in 12–14 weeks 
of the experiment – in formation of cirrhosis, 
thereafter the introduction of CCl4 was stopped. 
MSC suspension was introduced once into the 
caudal vein of the experimental group of ani­
mals, at the rate of 7 106/kg of animal’s weight. 
The injection of saline solution was given to 
the animals of control group. The changes, 
occurring in the liver of animals, were studied 
in dynamics for 13 weeks. Gradual restoration 
of liver was registered in experimental group; 
with the approximation to the norm for all the 
defined indices by the end of the experiment. 
There were no restoration changes in the con­
trol group [18].
Another model simulated chronic systemic 
damage of the organism. The object was the 
mice, injected twice a week for 12 weeks with 
carbon tetrachloride in the dose of 1.5 µl of 
30 % solution of CCl4 per one gram of the 
bodyweight. This procedure induced a severe 
damage of practically the whole organism [19]. 
12 weeks later the mice of experimental group 
were injected with MSC, in dose of 105 per 
animal. In different schemes of independent 
experiments, these were either fetal allogenic 
MSC, obtained from the embryo of the second 
line animal, or xenogenic MSC from Wharton’s 
jelly of the human umbilical cord. Some ani­
mals were taken out of the experiment after 3, 
9 and 12 weeks and the state of their organs 
was evaluated. The restoration of damaged 
organs was observed in MSC­injected animals. 
In the mice of control group there were either 
no positive changes or these were partial. The 
effect obtained on the models using other ani­
mals and other experimental pathologies was 
practically the same. For instance, the intro­
duction of MSC at rhinitis mucosa damage 
completely restored damaged tissues of mice 
and rats whereas there was no self­cure in the 
control group [20, 21]. The systemic or local 
introduction of MSC at the simulated allergic 
encephalomyelitis in rats resulted in clinical 
recovery of animals, whereas in the control 
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group the acute phase turned into the recurrent 
motor impairment [22; 23]. 
Noteworthy, in all these experiments, both 
on rats and mice, only single MSC injection 
was done after the pathology development. As 
the introduced cells were non­autologous, their 
replacement action via differentiation and res­
toration of damaged organs was almost impos­
sible. The results of PCR analysis, obtained by 
us on different models, demonstrated the dis­
appearance of the detected material 1–5 days 
after the MSC introduction [24]. The restora­
tion process without MSC injection lasted for 
many weeks.
The confirmation of the involvement of 
exogenous MSC in the mobilization of resident 
MSC was experimentally obtained. A matrix 
was implanted under the skin of the animal, 
and a damaging signal was imitated via the 
introduction of SDF1 source. Such carrier with 
chemokine was implanted under the skin of 
the ICR line mouse, imitating a damage zone. 
Then bone marrow MSC of GFP­transgenic 
mice were introduced into the caudal vein of 
the mice of experimental group. Several days 
later the explant was removed and analyzed 
for the presence of MSC. GFP marker was 
used to differentiate between resident and non­
resident MSC. It was established that in the 
variants with introduced exogenous cells the 
amount of matrix­attracted MSC was higher 
compared to the control, which proved the 
mobilization of resident MSC, mediated by the 
introduction of the exogenous ones [25].
The analysis of the obtained results, the 
literature data and current views on MSC sta­
tus in the organism allows us to draw several 
key assumptions. One of them is that MSC, 
introduced from outside (regardless of their 
nature, including autologous ones), and resi­
dent MSC, present in the organism all the time, 
are different cells by many biological proper­
ties. As has already been stated in the litera­
ture, MSC cultivated in laboratories on plastic, 
in nutrient media, in “clean” homogeneous 
culture outside the organism, are “a phenom­
enon of in vitro cultures” [26]. However, it is 
not the only problem. Prior to the introduction 
into the organism, MSC, extracted from it (or 
from a donor) are reproduced up to the amount 
of the “therapeutic dose”. The number of cells 
in this “dose” exceeds considerably the number 
of the resident cells, present at each given mo­
ment in the organism. “The dose” is usually 
calculated taking at least 106 MSC per 1 kg of 
bodyweight, which is 7 · 107 MSC for an “ave­
rage” human organism. As for systemic intro­
duction, the minimal single­step introduced 
doses are usually 5–10 times higher.
It may be stated that MSC in the organism 
are transitory. Their amount in the normal con­
ditions is not very large, reflecting some kind 
of “on­duty” state. In normal life of healthy 
individuals, MSC are massively formed out of 
their predecessors (progenitors) in the required 
amounts only in case of emergency needs – 
wounds, fractures, burns, etc. [27]. In such acute 
states, there is a release of a specific complex 
of signaling and informational molecules, gov­
erning the mobilization and rearrangement of 
metabolism of different cells of the systems of 
protection, pre ser vation and restoration, includ­
ing the stem cells [28]. The same is observed 
in the experimentally damaged organism. 
However, on the other hand, it was demon­
strated that in case of chronic impairments, stem 
cells may not be determined in blood at all [29], 
which may testify to the fact that the signaling 
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molecules of chronically damaged tissues either 
switch off or block the response of stem cells 
to the activation. One of these mechanisms, 
invol ving dipeptidyl peptidase­4, which blocks 
SDF­1, was described by Jixin Zhong and 
Sanjay Rajagopalan [30]. In this respect, MSC 
of the chronically sick organism are also 
“sick” – they are in a “chronically blocked or 
inactive” state, i.e. unable to function. As for 
MSC, cultivated in vitro, they are not affected 
by the organism and thus self­tune to the culti­
vation conditions rather fast. As a result, they 
differ in terms of status and condition from 
those still present in the organism. The inner 
rearrangements in MSC are almost not studied. 
However, as the conditions in different labora­
tories are similar, the standardisation of MSC 
preparation during re­programming seems rath­
er possible.
Many researchers often describe the results 
of a single introduction of MSC at chronic 
pathological processes, which in many cases 
(although not always) is sufficient for inducing 
a reliable therapeutic effect. In our experiments 
we also used a single introduction of allo­
genic and xenogenic MSC to avoid the effect 
of engraftment and differentiation. In our ex­
periments a single introduction of MSC was 
proven to be sufficient for therapeutic effect 
to start and develop, intensifying over the 
whole term of observation – up to 13 weeks. 
However, the allogenic and moreover xeno­
genic cells introduced from outside were 
shown in many experiments to be present in 
the recipient organism only for a few first days. 
Their main bulk does not enter the damage 
zone, being stuck in the lungs [30]. Our ex­
periments demonstrated that they were absent 
Fig. 1.
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in the damaged organs as early as after five 
days whereas the therapeutic effect developed 
for months, increasing week by week. This 
takes place at the introduction of any MSC 
from outside, including the cases when “exo­
ge nous”, foreign, ones are almost completely 
eliminated from the recipient organism just a 
few days after the introduction.
As for the “own” MSC of the organism, 
they may be formed from progenitors in un­
limited amount during any period, required for 
the restoration of any damage. Noteworthy, 
three basically different types of MSC are 
acknowledged in current literature (Fig. 1).
MSC of the first type, localized in the bone 
marrow, are the closest to the traditional no­
tions about stem cells and the most homoge­
neous, though they have some subpopulations 
of different origin [32; 33]. One of subpopula­
tions originates from neural crest in early em­
bryogenesis, the second ­ from some yet un­
known place but not neural crest, and the third 
one is composed of Schwann cells, marked as 
a specific subpopulation. There are no clear 
answers why there are three different MSC 
types, what their functions are and how they 
differ by their action in the organism.
MSC of the second type are well­described 
regional MSC, localized in different tissues, 
e.g. oval hepatocytes, stem cells of eyes, brain, 
etc. They fulfill a replacement function, i.e. if 
necessary differentiate into highly specialized 
cells and replace the dying or damaged ones. 
At first, they were considered as the derivatives 
of the “real” stem cells and the bone marrow – 
their central storage. Therefore, the stem cells 
in the organs were called “regional”. However, 
it is not a common belief, and the origin of stem 
cells in different tissues is yet to be established.
Most of MSC relate to the third type and 
actually they exist in the form of their prede­
cessors (progenitors) in the endothelium of 
small and medium vessels [6]. Vessels perme­
ate all tissues of all organs. Therefore, if re­
quired this source of MSC may be almost 
unlimited. However, this potential is realized 
mainly in response to the emergency signal, 
otherwise only an insignificant number of 
MSC “on duty” circulates. The place of “emer­
gency” is determined in the organism by the 
gradient of signaling molecules from the da­
ma ged zone, where the relevant chemokines 
are released. MSC are formed, mobilized and 
enter the affected zone to restore a specific 
damage in a specific organ [34]. The signaling 
molecules from the damaged zone cells “li­
cense” (commit, prime, polarize, etc.) MSC.
In addition to these described and localized 
sources of MSC there are some MSC, involved 
in the restoration of tissues and organs, which 
are formed by the potentially unlimited system 
of epithelial­mesenchymal/mesenchymal­epi­
thelial transitions [35–40]. 
Talking about restoration, one should men­
tion another, quite unique, group of self­repro­
ducing differentiated cells (i.e. self­preserving 
and self-restoring their deficiency in case of 
pathologies), which is composed of the cells of 
non-bone-marrow origin, defined as macro­
phages, originating from the yoke sac (prior to 
the growth of hematopoietic stem cells) [41–
43]. These are Kupffer cells, brain glia, alveolar 
macrophages, etc., which do not own any SC, 
reproducing themselves. Additionally, some 
highly differentiated cells (hepatocytes, for ex­
ample) are also capable of reproducing without 
de/re­differentiation, i.e. the differentiated cell 
divides into the differentiated duplicate.
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Summarizing the abovementioned, the hy-
pothesis of the mechanism of action of “ther-
apeutic MSC” may be formulated.
The restoration of damage, occurring after 
the introduction of “therapeutic MSC” from 
outside, is realized via the triggering mecha­
nism. The introduced MSC mobilize and acti­
vate the resident stem cells “on­duty” and 
launch the intense formation of own MSC out 
of progenitors of the vascular endothelium. 
When there is acute damage, this accelerates 
the curing and restoring process in injured tis­
sues (organs). In case of any chronic damage, 
lasting for a long time due to various reasons, 
a powerful impulse of signaling, trophic, and 
other biological molecules from the introduced 
MSC reprograms, mobilizes resident MSC, 
which had become insensitive due to chronic 
impairment, and they ensure their self­forma­
tion and restoration of damaged tissues (or­
gans) further on in the self­supporting mode. 
It has already been described in the literature 
that endothelial progenitor cells have their 
receptors of emergency (including SDF1 re­
ceptor) and are capable of getting activated 
and mobilized [44]. It may be assumed that 
other (hematopoietic, regional) stem cells are 
activated as well, ensuring the self­cure.
The abovementioned is true for the orga­
nism without any additional fundamental im­
pairments. If the latter are present, the mecha­
nism of self­restoration either fails to repair 
the damage, or is partially blocked. There may 
be two main types of such impairments.
The first one is conditioned by genetically 
determined impairments of the functions of a 
tissue or an organ. In extreme cases, these are 
clearly manifested hereditary diseases. In a 
milder (and more wide­spread) variant, these 
are “hereditary predispositions”. When imple­
mented (usually with the individual’s aging), 
there is a constant source of damage which is 
constitutive by its impact. Here the own cells 
of the organism are not capable of eliminating 
this source, no matter how much they are ac­
tivated or mobilized. However, MSC, intro­
duced from outside, can transfer the organism 
into a healthy phenotype at least for some time, 
activating the restoring, compensatory func­
tions of the cells of a chronically sick organ, 
enhancing their abilities of eliminating the 
pathological phenotype. Here a single intro­
duction of MSC will have only a temporary 
effect. Durable return to the functional norm 
would require the periodic introduction of 
MSC with the interval depending on the degree 
of impairment, determined by the “predisposi­
tion” gene.
The efficiency of multiple introduction of 
MSC was demonstrated by us in the experi­
ments using mice with a severe degree of 
systemic chronic damage. Single introduction 
of allogenic or xenogenic MSC is insufficient 
for restoration and some animals still perish, 
a larger number in the control, and a smaller 
in the experiment. When allogenic MSC were 
introduced three times, all the animals survived 
and restored the damaged organs. This is ex­
pected in case of various “predispositions”, 
affecting the restoration systems. A single in­
troduction of MSC induced the mobilization 
and activation of the resident SC. With no 
predisposition, such induction was sufficient 
for re­programming for further self­support of 
the restoring status of SC and the organism 
was cured. With predisposition, the induction 
diminished and the initially weaker animals, 
which had more severe pathology, died. 
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However, the three­time introduction of MSC 
resulted in 3­time periodical induction of the 
restoration systems and the restoration process 
was going on. There are some communications 
in the literature, stating that standard systems 
of treatment cannot be of the same efficacy for 
different individuals. Thus, an individualized 
analytical base should be developed] [45].
The second extreme type of impairments is 
related to the source of stable or increasing 
impairment, which cannot be eliminated by 
the organism itself. In this variant, the intro­
duced MSC cannot adjust the metabolism of 
a constitutively self­supported impairment. In 
case of allogenic origin, they are transitory in 
the organism, while the source of impairment 
works constantly. Even if syngen or autologous 
MSC are introduced into such an organism, 
the signaling and informational products of the 
constitutive source of damage will reconstruct 
the metabolism of the introduced MSC, ma­
king them either inactive, or “acting on the 
contrary”, supporting the pathology. Tumors 
are the most vivid [46; 47], although not the 
only example of the second type of impair­
ments. The chronic infections, leading to the 
death of all or most key differentiated cells of 
different organs (kidneys, glands of internal 
secretion, mucosa, etc.), such as hepatitis B 
virus, hepatitis C virus, HIV and others, will 
act in the same way. The scheme of MSC ap­
plication should be modified depending on the 
reasons of chronic disease. With no fundamen­
tal impairments, a stable effect may be ex­
pected from a single introduction of MSC in 
the restoring status. In case of impairments, 
caused by a constitutively acting damaging 
factor, MSC may be in another state (in ano­
ther polarization, as they now say) and serve 
merely as an additional mean. Another pro mi­
sing method is the transfection using a target 
gene, the product of which promotes the eli­
mi na tion of a constitutively acting damaging 
factor of non­autogenetic nature. At geneti­
cally determined predispositions, the introduc­
tion of MSC will be highly effective only in 
case of periodic application or in the variant 
of replacement action. However, regular mul­
tiple introduction of allogenic MSC may cause 
the avalanche of autoimmune diseases. So, it 
is necessary to use either only autologous, 
genetically modified MSC, or the allogenic 
ones, along with the procedures, eliminating 
the development of immune impairments. 
At present this is only a perspective at the 
level of rare laboratory investigations.
The fundamental and technological basis of 
the next level of replacement cell therapy is 
being developed now, and chronic pathologies 
will be the main target of its application. 
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Пусковий ефект «терапевтичних МСК»
В. А. Кордюм, Д. М. Іродов, Ю. В. Чайковський
Використання МСК як терапевтичного препарату не 
завжди виявляється високоефективним. У статті аналі­
зуються можливі причини такої дії МСК і обґрунтову­
ється концепція їх «пускового ефекту». Він полягає в 
тому, що сигнальні молекули, що виділяються МСК, що 
вводяться в організм, з одного боку зменшують ступінь 
ураження клітин, підтримуючи і відновлюючи пошко­
джені клітини, а з іншого – призводять до мобілізації і 
активації власних (резидентних) СК, що в подальшому 
реалізують заміщення уражених клітин. Реалізація влас­
не терапевтичного ефекту залежить від наявності або 
відсутності генетично детермінованих порушень.
К л юч ов і  с л ов а: мезинхімальні стовбурові кліти­
ни, пусковий ефект, мобілізація, активація.
Пусковой эффект «терапевтических МСК» 
В. А. Кордюм, Д. М. Иродов, Ю. В. Чайковский 
Использование МСК в качестве терапевтического 
препарата не всегда оказывается высокоэффектив­
ным. В статье анализируются возможные причины 
такого действия МСК и обосновывается концепция 
их «пускового эффекта». Он заключается в том, что 
сигнальные молекулы, выделяемые введенными в 
организм терапевтическими МСК (имеют двойное 
действие), с одной стороны уменьшают степень 
поражения клеток, поддерживая и восстанавливая 
поврежденные клетки, а с другой – приводят к 
мобилизации и активации собственных (резидент­
ных) СК, которые в дальнейшем и реализуют за­
мещение пораженных клеток. Реализация собствен­
но терапевтического эффекта зависит от наличия 
или отсутствия генетически детерминированных 
нарушений.
К л юч е в ы е  с л ов а: мезенхимальные стволовые 
клетки, пусковой эффект, мобилизация, активация.
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